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Abstract
Objectives To analyse the performance of the English Stop Smoking
Services from 2001/02 to 2010/11.
Design Analysis of national service monitoring data.
Setting England.
Participants Smokers recorded as having been treated by English stop
smoking services between April 2001 and March 2011.
Main outcome measures Annual figures for the number of quit dates
set (throughput), the percentage of these that led to biochemically verified
abstinence after four weeks (four week quit rate), and the “impact” in
terms of the number of four week quitters beyond those who it is
estimated would have stopped with only a prescription for smoking
cessation treatment; characteristics of smokers being treated, medication
used, and mode of delivery (for example, one to one, group based);
variability across local services in throughput, four week quit rates, and
impact for 2010/11.
Results Throughput rose from 227 335 in 2001/02 to 787 527 (8% of
all smokers) in 2010/11. The percentage of four week quitters declined
slightly from 35% to 34%. Impact rose from 22 933 four week quitters
created in 2001/02 to 72 411 in 2010/11 (corresponding to an estimated
21 723 12 month quitters). The services were successful in reaching
disadvantaged smokers; 54% (n=425 684) were in receipt of free
prescriptions in 2010/11. Substantial variation existed across local
services in throughput, success rates, and impact.
Conclusions The English stop smoking services have had an increasing
impact in helping smokers to stop in their first 10 years of operation and
have successfully reached disadvantaged groups. However, performance
across local services has varied considerably.
Introduction
Stopping smoking after early adulthood adds an average of three
months’ healthy life expectancy for every year of smoking
avoided, but for most smokers quitting is extremely difficult,
with fewer than 5% of unaided quit attempts lasting 12
months.1 2 Evidence from multiple randomised controlled trials
shows that face to face behavioural support for smoking
cessation (also referred to as counselling and psychological
support) provided individually or in groups can improve
cessation rates and save lives very cheaply.3 4 The English
National Health Service provides this support on top of
medication to aid cessation. This takes the form of a network
of “stop smoking services.” Other countries have since followed
this model for helping their smokers to stop.5 Extending global
implementation of Article 14 of theWorld Health Organization
Framework Convention on Tobacco Control, which focuses on
treatment for tobacco dependence, and changes in funding
arrangements in England, make it timely to examine the effect
of the English stop smoking services.6 This paper reports an
evaluation of 10 years of operation of these services.
In 1998 the UK government published a white paper entitled
“Smoking Kills,” outlining its plans to reduce the massive toll
of death and disease in the country caused by smoking.7 It
included a range of evidence based policies such as tax increases
and use of mass media campaigns. One innovative component
of these plans was establishing a national network of stop
smoking services to ensure that every smoker in the country
who wanted help with stopping would have access to evidence
based behavioural support on top of a prescription for a smoking
cessation medication, as recommended in clinical practice
guidelines.8
The stop smoking services in England are under local direction.
Until 2013, this was through 151 primary care trusts; since April
2013, it has been through local authorities. Each local area can
configure its service as it sees fit but is encouraged to follow
national guidance.9 Services are expected to offer behavioural
support and medication to all smokers in their community and
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also to ensure that they are treating smokers proportionally to
their demographics in their area (for example, if 60% of the
local smoking population is from disadvantaged groups, the
service will be expected to treat at least that proportion of
disadvantaged smokers).
The behavioural support should involve a session before the
quit date in which smokers discuss medication options and
preparation for the quit date, a quit date session, and then weekly
sessions for at least four weeks afterwards. The sessions seek
to maintain motivation to sustain abstinence, provide advice on
avoiding or coping with cigarette cravings and adverse
withdrawal symptoms, and optimise use of medication.9
Medication should be offered for at least eight weeks in the case
of nicotine replacement therapy and 12 weeks in the case of
varenicline.8 Evidence from randomised controlled trials and
an early evaluation of the services indicates that when these are
provided optimally, the proportion of users who stop for four
weeks should be approximately 50%, with 15% lasting 12
months, compared with 15% at four weeks and less than 5% at
12 months if these smokers tried to stop unaided.1 10 11
The services are free to users. A small prescription charge for
medications is payable; people on low incomes, over 60 years
of age, or pregnant/postpartum and patients with certain medical
conditions are exempt.
From the outset, each local stop smoking service has been
required to submit quarterly data to the Department of Health
on numbers of quit dates set (throughput), end of treatment
abstinence rates (four weeks after the target quit date),
characteristics of smokers using the services, and type of
treatment provided.12 These data provide a resource for
evaluating the stop smoking services and for examining trends
over time.
When estimating the impact of any stop smoking treatment
programme, one must take account of the fact that a proportion
of the smokers attending would have stopped without support
or with a lower level of support. This requires use of a
comparator; in the case of the English stop smoking services,
the most appropriate comparator involves assuming that all
those attending the services would instead have tried to stop
with a prescription for a smoking cessation medication but
without the specialist behavioural support package. This is
conservative because it focuses only on the behavioural support
element (not the medication) and takes no account of possible
effects that having services may have on promoting quit
attempts. However, it permits assessment of the specific effect
of having these services as opposed merely to providing stop
smoking medication on prescription.
Research from numerous randomised controlled trials and cohort
studies shows that 70% of people who are abstinent at four
weeks will relapse by 12 months,10 and up to 35% of those
remaining will relapse after that.13 With that information and
knowledge of the background quit rates in the population, we
can estimate the numbers of permanent ex-smokers generated
by the services from the four week quit rates.13
This analysis attempted to answer the following research
questions. How have throughput, success rates, and impact of
the English stop smoking services changed in the past 10 years
of their operation? To what extent have the services met the
needs of different sub-populations and particularly economically
disadvantaged smokers? How far have throughput, four week
quit rates, and impact varied between local services?
Methods
We used mandatory monitoring data collected by the Health
and Social Care Information Centre to do the analyses reported
in this paper.12 We analysed service data for every year since
2001/02, when the services were implemented nationwide with
full access to stop smoking medication.
“Treated smokers” included in the returns were service attenders
who had set a quit date and received an offer of a structured,
multi-session intervention (delivered by a stop smoking adviser).
An individual smoker may be treated more than once and so
may appear in the data on more than one occasion in a single
year or over several years. However, the vast majority of those
treated in a year are “unique users.” Analysis of a representative
sample of 70 services using the Quit Manager database for
2010/11 showed that 92% of treated smokers were counted only
once that year, 7% were counted twice, and 1% were counted
three times (E Croghan, personal communication, July 2012).
The data collected for each treated smoker included sex, age,
ethnic group, eligibility for free prescriptions (from 2008/09),
pregnancy, and type of medication used (none, nicotine
replacement therapy, bupropion, and varenicline). From 2008/09
the mode of delivery of the behavioural support was recorded:
closed group (same group of smokers seen together regularly),
open/rolling group (smokers at different stages of their quit
attempt, regular meetings offered), one to one support (one
adviser, one smoker; specified time and place), couple/family
support (adviser and up to six members of same
family/friendship group), drop-in support (one to one, specified
venue but unallocated time within time slot), telephone support
(one to one support over the phone), and “other” (for example,
text messaging or internet based support).
Outcome was recorded in terms of whether a quit attempt
resulted in a biochemically verified four week quitter. Four
weeks after the target quit date (usually at the last treatment
session), service users were asked whether they had smoked at
all in the previous two weeks. They were thus allowed a two
week grace period to get their quit attempt started. If they
indicated that they had not smoked at all, good practice required
the stop smoking adviser to take an expired air carbonmonoxide
reading.9 If the reading was below 10 ppm, the four week quit
status would be regarded as confirmed. Lower carbonmonoxide
thresholds have been proposed, but research shows that these
do not substantially affect the results.14 As is standard practice
in smoking cessation,15 service users who did not return for the
four week session or for whom an expired air carbon monoxide
reading was not available were counted as having resumed
smoking.
Another option in terms of calculating the four week quit rate
would have been to use the number of people who self reported
as having stopped at four weeks irrespective of whether the
claim was biochemically verified. However, this would have
provided an inflated estimate given the known degree of
misreporting in these situations.
We defined the “impact” of the stop smoking services as the
number of four week quitters generated over and above those
that would have been expected had the same smokers received
only a prescription for a stop smoking medication. The purpose
of the measure was to provide the most accurate assessment of
the effect of the behavioural support provided by the service.
A figure of 25% was arrived at as the best estimate for the
expected biochemically verified four week quit rate with
prescription medication alone. This figure was based on the four
week success rate in smokers trying to stop unaided multiplied
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by the rate ratio of 1.6 attributable to medications fromCochrane
reviews.1 16 Thus smokers in control conditions of smoking
cessation trials achieve four week quit rates of approximately
15%. Nicotine replacement therapy (the most popular
medication) to aid cessation increases this by approximately
60%, yielding a predicted four week quit rate of 25% for
smokers motivated to seek help with quitting and using only
nicotine replacement therapy. Using this information, we
calculated impact as the difference between the achieved four
week quit rate and 25%, multiplied by the number of quit dates
set.
Results
Annual throughput increased from 227 335 quit dates set in
2001/02 to 787 527 in 2010/11 (table 1⇓; fig 1⇓). The quit rate
reduced slightly from 35% to 34%, with a dip to 31% in
2007/08. This meant that the total number of four week quitters
rose from 79 767 to 269 293. The impact (number of four week
quitters estimated to be created beyond what would be expected
with medication alone) rose from 22 933 to 72 411.
Table 2⇓ shows that the services attracted an increasing
proportion of men and primarily served smokers aged over 35,
and that the proportion of smokers from ethnic minority groups
who attended almost doubled to 7%. The proportion of smokers
eligible for free prescriptions rose considerably between 2008/09
and 2010/11 until it comprised more than half of those treated.
Table 3⇓ shows the types of medication provided. Throughout
the period of study, nicotine replacement therapy was the
dominant medication. Initially, bupropion was also used by a
substantial minority; by 2010/11, this had been replaced by
varenicline, which became available in 2007/08. Table 4⇓ shows
that by far the most common mode of behavioural support was
one to one support.
Figure 2⇓ shows the variation in throughput, four week quit
rates, and impact of the 151 local stop smoking services in
2010/11. Throughput and impact are expressed per 100 000
head of local population to take account of differences in size
of primary care trusts. The trusts in each case are shown from
highest to lowest, left to right. The order of the trusts is different
for each outcomemeasure. In the case of impact, several primary
care trusts were rated as zero because their four week quit rates
were below 25%.
We found a moderate negative correlation between four week
quit rate (percentage of those treated who were abstinent at four
weeks) and throughput (number of quit dates set) per 100 000
head of population (Pearson r=−0.45, P<0.001). Impact was
highly correlated with four week quit rate (Pearson r=0.86,
P<0.001) but negatively correlated with throughput (Pearson
r=−0.26, P<0.01).
Discussion
The English stop smoking services have had an increasing
impact on national smoking cessation since 2001 by increasing
throughput with only a small decrease in the percentage of those
treated who succeed. They have been successful in reaching
economically disadvantaged smokers, with more than half of
those treated being eligible for free prescriptions. The quit rates
of around 35% at four weeks have been generally below what
would be expected from an optimal service (around 50%) but
higher than would be expected if the smokers attending had
received only a prescription for a stop smoking medication
(25%). We found substantial local variation in throughput, four
week quit rates, and impact. Services with higher throughput
have lower success rates, and impact is strongly associated with
percentage of those treated who quit rather than with throughput.
Bearing in mind the difficulty in quitting experienced by
smokers who typically attend stop smoking services, even a
35% four week quit rate represents a substantial impact when
applied to the nearly 800 000 quit dates set with the services in
2010/11 (700 000 smokers, or 8% of the 9 million smokers in
England). Using an estimate of 70% relapse between four weeks
and 12 months, the services generated 21 723 12month quitters
in 2010/11 (30% of the four week impact). According to
standard cost effectiveness tables developed for the purpose,13
this is expected to result in 24 413 additional life years
(discounted by 3.5% per year as recommended by the National
Institute for Health and Care Excellence (NICE)). The estimated
cost of the service in 2010/11 was £84m (€97m; $128m)
excluding medication costs9—£107 per quit date set, £312 per
four week quitter, and £3441 per discounted life year saved,
which is less than 20% of the NICE threshold.
The wide variation in throughput, four week quit rates, and
estimated impact of the local services needs further
investigation. Other research on a sample of local services
suggests that it cannot be accounted for by variation in the
characteristics of smokers in the local population.17A substantial
part of it can be attributed to differing degrees to which services
follow evidence based practice, including use of specialist stop
smoking advisers and ensuring that smokers have full access to
optimummedication options.17 Thus, services that make greater
use of group based support and specialist services delivered by
staff employed specifically for the purpose, and who provide
varenicline or combination nicotine replacement (transdermal
patch plus a faster acting product), achieve the highest success
rates.17 In addition, services that offer more sessions of support
and where the behavioural support is more in line with what
has been shown to be effective in randomised controlled trials
get better success rates.18 The National Centre for Smoking
Cessation and Training (NCSCT) was set up by the Department
of Health in 2008 to reduce this variability by establishing best
practice, implementing a training and assessment programme
to ensure a minimum level of competence of stop smoking
advisers (www.ncsct.co.uk).
As with any routine data monitoring, the findings reported here
are subject to several potential sources of error and bias. Focus
on four week quitters verified by carbon monoxide would lead
to underestimation of effectiveness of services that have not
followed guidance in attempting to ensure that all claims of
abstinence are biochemically verified. This could be why several
services had success rates of less than 25%. Also, these services
may not have been providing high quality support.
With strong pressure on primary care trusts to achieve four week
quit targets, some services may also have adopted more lenient
criteria when determining throughput and four week quit status
(for example, counting smokers as having quit through the
service when they were detected as a quitters only through
questioning after the fact). The Department of Health has
commissioned the NCSCT to develop a process for reviewing
service provision and monitoring to mitigate variability in
reporting practice.19 Several sensitivity analyses to establish a
plausible range within which the likely effects of the services
lie would be possible; however, even under pessimistic
assumptions, the number of life years gained and cost
effectiveness place them among the most impactful and cost
effective parts of national healthcare provision. Finally, the
figure for impact may be an underestimate if existence of stop
smoking support has led more people to try to quit than would
have done otherwise.
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Other countries that have national services, or regions that have
regional ones, can be reassured that providing this kind of
“individual level” public health intervention at a “population
level” is possible. However, they can also learn lessons from
the English services, documented in this paper, about the need
to pay close attention to variability in performance, and the
importance of rigorous monitoring and finding ways of fostering
good practice.
Conclusion
Over 10 years of operation, the English stop smoking services
have increased their reach and impact threefold. In 2010/11 they
were used by some 8% of all smokers, including a high
proportion of those with economic disadvantage, and can
estimated to have helpedmore than 20 000 to achieve long term
abstinence, saving almost 25 000 life years. However,
considerable variability in outcomes exists across local areas.
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What is already known on this topic
The English stop smoking services have been successful in recruiting large numbers of smokers
What this study adds
This is the first published estimate of the impact of the English stop smoking services and overview of performance over its first 10 years
of operation
It shows that the services have trebled their impact in terms of numbers of smokers led to stop by increasing the numbers treated with
only a small decline in the success rates
However, substantial variability between local services is a matter that requires attention
Tables
Table 1| Throughput, number and percentage of four week quitters, and impact of English stop smoking services from 2001/02 to 2010/11
Impact (No of 4 week quitters created)No (%) 4 week quittersThroughput (No)Year
22 93379 767 (35)227 3352001/02
24 44983 163 (35)234 8582002/03
37 187127 493 (35)361 2242003/04
58 633191 025 (36)529 5672004/05
59 924210 717 (35)603 1742005/06
47 950198 052 (33)600 4102006/07
38 670208 742 (31)680 2892007/08
56 463224 278 (33)671 2592008/09
67 329256 713 (34)757 5372009/10
72 411269 293 (34)787 5272010/11
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f4921 doi: 10.1136/bmj.f4921 (Published 20 August 2013) Page 5 of 9
RESEARCH
Table 2| Characteristics of stop smoking service users. Values are numbers (percentages)
Aged ≥35Minority ethnic groupFemaleEligible for free prescriptionsYear
168 173 (74)7 366 (4)129 101 (57)NA2001/02
166 618 (71)8 252 (4)134 963 (57)NA2002/03
252 659 (70)14 896 (4)205 768 (57)NA2003/04
367 661 (69)24 012 (5)302 035 (57)NA2004/05
407 100 (68)32 348 (6)341 295 (57)NA2005/06
401 125 (67)37 035 (6)334 099 (56)NA2006/07
464 825 (68)37 734 (6)373 000 (55)NA2007/08
464 825 (66)45 228 (7)357 339 (53)295 509 (44)2008/09
497 342 (66)57 849 (7)393 805 (52)381 060 (50)2009/10
522 037 (66)57 849 (7)411 392 (52)425 684 (54)2010/11
NA=not applicable.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f4921 doi: 10.1136/bmj.f4921 (Published 20 August 2013) Page 6 of 9
RESEARCH
Table 3| Percentage of quit attempts involving different types of stop smoking medication. Values are numbers (percentages)
Other/not knownNoneVareniclineBupropionNRTYear
11 887 (5)24 389 (11)NA44 286 (19)142 260 (63)2001/02
9 140 (4)19 784 (8)NA26 773 (11)175 674 (75)2002/03
22 611 (6)27 623 (8)NA30 158 (8)277 041 (77)2003/04
31 473 (6)35 472 (7)NA33 931 (6)424 509 (80)2004/05
33 814 (6)40 306 (7)NA30 559 (5)494 105 (82)2005/06
33 656 (6)38 617 (6)NA27 395 (5)496 932 (83)2006/07
40 977 (6)42 647 (6)97 259 (14)22 348 (3)474 311 (70)2007/08
32 445 (6)35 774 (5)134 949 (20)11 278 (2)449 876 (67)2008/09
31 093 (5)39 222 (5)175 380 (23)9 509 (1)493 459 (65)2009/10
28 557 (4)39 392 (5)203 338 (26)6 515 (1)498 399 (63)2010/11
NA=not applicable; NRT=nicotine replacement therapy.
Row percentages may not add to 100 because of up to 2% receiving more than one medication, not recorded here.
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Table 4| Mode of service delivery. Values are numbers (percentages)
OtherFamily/coupleTelephoneClosed groupRolling groupDrop-inOne to oneYear
20 088 (3)4 764 (1)6 920 (1)18 123 (3)31 089 (5)63 926 (10)526 346 (78)2008/09
16 175 (2)6 268 (1)9 041 (1)16 680 (2)33 296 (4)80 448 (11)595 629 (79)2009/10
7 309 (1)7 822 (1)11 576 (1)13 899 (2)26 142 (3)84 743 (11)636 036 (81)2010/11
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f4921 doi: 10.1136/bmj.f4921 (Published 20 August 2013) Page 8 of 9
RESEARCH
Figures
Fig 1 Annual number of quit dates set in English stop smoking services 2001/02 to 2010/11
Fig 2 Throughput, four week quit rates, and impact of local stop smoking services in 2010/11
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